OLMA — Olema Pharmaceuticals Inc

Stock analysis, trade plans, and proprietary indicators by Trend Edge.

About Olema Pharmaceuticals Inc

Olema Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women's cancers. The company's lead product candidate is palazestrant, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 3 clinical trial for the treatment of recurrent, locally advanced, or metastatic ER-positive, human epidermal growth factor receptor 2-negative … Read full Trend Edge analysis →

Trend Edge Proprietary Indicators

Key Metrics

Current Price$12.91
Market Cap$1.22B
Float59.4M
Shares Outstanding87.3M
vs. Analyst Target+223.9% to analyst PT
Dividend RateNone
Analyst Target Price$41.82 (8 analysts)

Financial History

Annual Revenue & Earnings History

YearRevenueNet IncomeGross ProfitEBITDA
2020 N/A -$22.1M -$11,000 -$21.5M
2021 N/A -$71.1M -$1.7M -$71.3M
2022 N/A -$103M -$1.7M -$107M
2023 N/A -$96.7M -$377,000 -$105M
2024 N/A -$129M -$393,000 -$142M
2025 N/A -$162M N/A -$178M

Recent Quarterly Revenue & Net Income

QuarterRevenueNet Income
Jun 2025 N/A -$43.8M
Sep 2025 N/A -$42.2M
Dec 2025 N/A -$46.1M
Mar 2026 N/A -$53.1M

Ownership & Float

Insider Ownership1.8%
Institutional Ownership119.4%
Short Float22.0%
% of All Funds Holding2.26%
Number of Funds Holding186

Current Moving Averages

Trend Edge tracks near-term, medium-term, cyclical, and secular moving averages across weekly and monthly timeframes to identify trend structure at every horizon.

TimeframeSMAValueTrend Context
Weekly10-Week SMA$14.66Near-term / short-term trend
Weekly40-Week SMA$17.36Medium-term trend
Weekly80-Week SMA$11.34Cyclical trend (business cycle)
Weekly200-Week SMA$9.87Secular trend (multi-year)
Monthly10-Month SMA$16.97Near-term monthly trend
Monthly20-Month SMA$11.56Medium-term monthly trend
Monthly40-Month SMA$10.94Secular monthly trend

Volume Shelves — Support & Resistance

Trend Edge identifies volume shelves: price zones where historically elevated trading volume creates structural support or resistance. A volume shelf forms when a disproportionate share of cumulative volume was transacted at a specific price level, making it a high-conviction anchor for future price reactions.

Price LevelTypeVolume RatioAge
$23.50 resistance 1.26x 1 months ago
$9.00 support 4.55x 5 months ago
$5.50 support 1.54x 7 months ago
$3.80 support 1.28x 12 months ago

Historical Earnings Reactions (23 events)

TimeframeAvg ReturnMedianWin RateBestWorst
Gap 1.45% 0.15% 52.17% 15.16% -5.38%
1 Day -0.78% -0.72% 39.13% 16.19% -26.74%
1 Week 0.92% -1.28% 39.13% 131.49% -35.55%
2 Weeks 2.28% -12.39% 31.82% 199.66% -30.76%
1 Month 13.64% -7.67% 45.45% 279.89% -66.21%

Next earnings: July 31, 2026 (64 days away)

Seasonality & Day-of-Week Patterns

Monthly Seasonality

Insufficient historical data for monthly seasonality analysis (requires 7+ years of data).

Day-of-Week Tendencies

DayAvg ReturnWin RateSamples
Monday -0.47% 47.1% 257
Tuesday 0.52% 49.5% 287
Wednesday 0.45% 51.1% 284
Thursday -0.17% 42.4% 276
Friday 0.15% 48.2% 278

Top Institutional Holders

Institutional holder breakdown coming soon.

Total institutional ownership: 119.4%

Insider Transactions — Smart Summary

Total insider ownership: 1.8%

12-Month Insider Activity Summary

Total Filings10
Net Value-$13.8M
Net Shares Change-344,701
% of Float-0.6%
C-Suite Filings5
Clusters Detected2

Key Insiders

NameTitleNet ValueFilingsActivity
CLARK IAN T -$6.7M 1 1 sell
Zojwalla Naseem Chief Medical Officer -$5.9M 1 1 sell
Myles David C. CH. DISCOV. and NON-CLIN DEV OFF -$4.2M 2 3 sell
Kovacs Shane William Charles CH. OPERATING and FINANCIAL OFF. -$3.0M 1 1 sell
Mitchell Shawnte CHIEF LEGAL OFFICER -$776,704 1 1 sell
Harmon Cyrus -$657,435.11 4 5 sell

Transaction Clusters

PeriodFilingsInsidersNet ValueSeniority
2025-12-23 – 2025-12-29 4 4 -$14.2M 2 C-suite
2026-01-14 – 2026-01-21 4 3 -$6.0M 2 C-suite

Significant Filings

DateInsiderTitleNet ValuePrice After
2026-01-14 Myles David C. CH. DISCOV. and NON-CLIN DEV OFF -$2.6M Transaction at $20.48, now -37.0%
2026-03-05 Mitchell Shawnte CHIEF LEGAL OFFICER -$776,704 Transaction at $14.08, now -8.3%
2025-12-23 Zojwalla Naseem Chief Medical Officer -$5.9M Transaction at $19.91, now -35.2%
2026-01-15 Kovacs Shane William Charles CH. OPERATING and FINANCIAL OFF. -$3.0M Transaction at $28.70, now -55.0%
2025-12-23 Myles David C. CH. DISCOV. and NON-CLIN DEV OFF -$1.6M Transaction at $30.46, now -57.6%
2025-09-18 Harmon Cyrus -$204,840.5 Transaction at $8.21, now +57.3%

View full insider transaction history on Trend Edge →

AI Consult Analysis

Trend Edge's AI Consult feature delivers a comprehensive, multi-layer trade plan for Olema Pharmaceuticals Inc (OLMA) powered by Claude Opus — Anthropic's most capable AI model. The analysis covers five layers: technical analysis (near-term, medium-term, cyclical, and secular trend, momentum, volume shelf support and resistance, breakout and breakdown signals), qualitative analysis (business model, competitive moat, sector dynamics), insider sentiment (buy and sell signals from executive and director transactions), share stats analysis (institutional accumulation, fund positioning, short float squeeze potential), and fundamental analysis (valuation, revenue growth, profit margin, earnings quality).

AI Consult synthesizes all five layers into a single bullish or bearish thesis with explicit entry, exit, stop loss, and take profit levels — giving you a complete, AI-powered trade plan with defined risk/reward. Whether you are building a long position, initiating a short, or looking for a reversal setup, AI Consult identifies the highest-probability signal from the current trend.

Get the full AI Consult analysis for OLMA on Trend Edge →